Alliance for Pandemic Preparedness

January 4, 2021

Efficacy and Safety of the MRNA-1273 SARS-CoV-2 Vaccine



Keywords (Tags):

Results from a phase 3 randomized, observer-blinded, placebo-controlled trial of the Moderna SARS-CoV-2 vaccine candidate (mRNA-1273) indicated that the vaccine showed 94.1% efficacy at preventing COVID-19, including severe disease. The trial enrolled 30,420 volunteers, and symptomatic illness was confirmed in 185 participants in the placebo group and in 11 participants in the vaccine group. Efficacy was similar across key secondary analyses, including in participants who had evidence of SARS-CoV-2 infection at baseline and analyses in participants 65 years of age or older. Severe COVID-19 occurred in 30 participants, with one fatality; all 30 were in the placebo group. Serious adverse events were rare, and the incidence was similar in the two groups.

Baden et al. (Dec 30, 2020). Efficacy and Safety of the MRNA-1273 SARS-CoV-2 Vaccine. New England Journal of Medicine.